Castle Biosciences director granted 11,766 RSUs

Caple Kim reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Caple Kim reported acquisition or exercise transactions in this Form 4 filing.

Castle Biosciences director Kim Caple received a grant of 11,766 Restricted Stock Units (RSUs) linked to the company’s common stock. Each RSU represents one share of common stock, for a total underlying amount of 11,766 shares. The RSUs vest in full on the earlier of the one-year anniversary of May 28, 2027, or the day immediately before the next Annual Meeting of Stockholders following the grant date. After this grant, Caple’s reported derivative holdings from this award total 11,766 RSUs.

Insider Trade Summary

Grant/Award: 11,766 shares

Grant/Award 1 txn

Insider Caple Kim

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	11,766	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 11,766 contracts (Direct)

Footnotes (2)

1. F1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
2. F2. The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 28, 2027, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant.

Key Figures

RSUs granted: 11,766 units Underlying common shares: 11,766 shares Grant price per RSU: $0.0000 per unit +1 more

4 metrics

RSUs granted 11,766 units Restricted Stock Units awarded to director on May 28, 2026

Underlying common shares 11,766 shares Common Stock underlying the RSU grant

Grant price per RSU $0.0000 per unit Non-cash compensation award

Vesting trigger date reference May 28, 2027 One-year anniversary referenced for full vesting condition

Key Terms

Restricted Stock Units, RSU, Annual Meeting of Stockholders

3 terms

Restricted Stock Units financial

"Each Restricted Stock Unit ("RSU") represents the right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSU financial

"Each Restricted Stock Unit ("RSU") represents the right to receive one share"

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

Annual Meeting of Stockholders financial

"the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Castle Biosciences (CSTL) director Kim Caple report on this Form 4?

Kim Caple reported receiving a grant of 11,766 Restricted Stock Units. These RSUs are compensation-linked derivatives that can settle into 11,766 shares of Castle Biosciences common stock once vesting conditions are met.

How many Restricted Stock Units did Kim Caple receive from Castle Biosciences (CSTL)?

Kim Caple received 11,766 Restricted Stock Units from Castle Biosciences. Each RSU corresponds to one share of common stock, so the award covers 11,766 underlying shares if fully vested and settled.

When do Kim Caple’s Castle Biosciences (CSTL) RSUs vest?

The RSUs vest in full on the earlier of the one-year anniversary of May 28, 2027, or the day immediately preceding the next Annual Meeting of Stockholders. This structure ties vesting to either time passage or the company’s next shareholder meeting.

Does the RSU grant to Kim Caple involve any cash transaction in CSTL stock?

The RSU grant has a stated price per unit of $0.0000, indicating no cash purchase or sale took place. It is a stock-based compensation award rather than an open-market transaction in Castle Biosciences shares.

How many Castle Biosciences (CSTL) RSUs does Kim Caple hold after this transaction?

Following this grant, Kim Caple’s reported holdings from this RSU award total 11,766 units. Each unit represents the right to receive one share of Castle Biosciences common stock once vesting conditions are satisfied.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 04:47 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Caple Kim

(Last) (First) (Middle)

C/O CASTLE BIOSCIENCES, INC.

1500 W. PARKWOOD AVE SUITE 400

(Street)

FRIENDSWOOD TEXAS 77546

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CASTLE BIOSCIENCES INC [ CSTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	05/28/2026		A		11,766		(2)	(2)	Common Stock	11,766	$0	11,766	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

2. The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 28, 2027, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant.

Remarks:

	/s/ Frank Stokes, Attorney-in-fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)